Dr. Reddy’s Laboratories Ltd ADR

RDY

New York Stock Exchange. Currency in USD

52.85 +0.16 ( +0.30% )

Real time prices: December 19

Market Cap.
8.77B
Beta (5Y monthly)
0.19
Price/Earnings
19.05
EPS (TTM)
2.82
Forward Dividend
0.34 (0.64%)
Ex-Dividend Date
Jul 11, 2022
Volume
110,854
1y Target Est.
62.37
Day's Range
52.76
-
53.62
52 Week's Range
47.88
-
58.98

Historical Summary

Performance
EPS growth
Share Buybacks

About Dr. Reddy’s Laboratories Ltd ADR

Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Website
https://www.drreddys.com
Exchange
New York Stock Exchange (XNYS)
Shares Outstanding
165.96M
Employees
24795
Address
8-2-337, Road No. 3, Hyderabad, India, 500034
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Latest news

Doctor Reddy's (RDY) Gains But Lags Market: What You Should Know
Doctor Reddy's (RDY) Gains But Lags Market: What You Should Know

Doctor Reddy's (RDY) closed at $54.62 in the latest trading session, marking a +0.57% move...
By Zacks Investment Research - 6 weeks ago

Zacks Industry Outlook Highlights Dr. Reddy's, Amphastar Pharmaceuticals and Sol-Gel Technologies
Zacks Industry Outlook Highlights Dr. Reddy's, Amphastar Pharmaceuticals and Sol-Gel Technologies

Dr. Reddy's, Amphastar Pharmaceuticals and Sol-Gel Technologies have been highlighted in this Industry Outlook article.
By Zacks Investment Research - 7 weeks ago

Doctor Reddy's (RDY) Gains As Market Dips: What You Should Know
Doctor Reddy's (RDY) Gains As Market Dips: What You Should Know

In the latest trading session, Doctor Reddy's (RDY) closed at $53.25, marking a +0.02% move...
By Zacks Investment Research - 7 weeks ago

3 Generic Drug Stocks to Watch Amid Inflation Pressures
3 Generic Drug Stocks to Watch Amid Inflation Pressures

The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs...
By Zacks Investment Research - 7 weeks ago

New Strong Buy Stocks for November 17th
New Strong Buy Stocks for November 17th

PSX, DCP, RDY, PDFS and CRZBY have been added to the Zacks Rank #1 (Strong...
By Zacks Investment Research - 10 weeks ago

Doctor Reddy's (RDY) is a Top-Ranked Momentum Stock: Should You Buy?
Doctor Reddy's (RDY) is a Top-Ranked Momentum Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the...
By Zacks Investment Research - 11 weeks ago

Dr. Reddy's (RDY) Earnings & Revenues Trump Estimates in Q2
Dr. Reddy's (RDY) Earnings & Revenues Trump Estimates in Q2

Dr. Reddy's (RDY) earnings and sales beat estimates in second-quarter fiscal 2023.
By Zacks Investment Research - 13 weeks ago

Doctor Reddy's (RDY) is a Top-Ranked Value Stock: Should You Buy?
Doctor Reddy's (RDY) is a Top-Ranked Value Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on...
By Zacks Investment Research - 16 weeks ago